Free Trial
NASDAQ:CLSD

Clearside Biomedical Q2 2025 Earnings Report

Clearside Biomedical logo
$3.96 -0.43 (-9.79%)
Closing price 09/23/2025 04:00 PM Eastern
Extended Trading
$4.28 +0.32 (+8.08%)
As of 04:32 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Clearside Biomedical EPS Results

Actual EPS
-$0.90
Consensus EPS
-$1.80
Beat/Miss
Beat by +$0.90
One Year Ago EPS
N/A

Clearside Biomedical Revenue Results

Actual Revenue
$0.49 million
Expected Revenue
$0.50 million
Beat/Miss
Missed by -$8.00 thousand
YoY Revenue Growth
N/A

Clearside Biomedical Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Friday, August 8, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Clearside Biomedical's Q3 2025 earnings is scheduled for Tuesday, November 11, 2025, with a conference call scheduled on Friday, November 7, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Earnings Documents

Clearside Biomedical Earnings Headlines

Wall Street Zen Upgrades Clearside Biomedical (NASDAQ:CLSD) to Sell
China’s message to Trump
Did China just fire shots at America? Last week, in Tiananmen Square, China put on a chilling display of military power. Fighter jets, tanks, AI-guided drones — all paraded under the red flag, in front of Vladimir Putin, Kim Jong Un, and more than two dozen world leaders.tc pixel
See More Clearside Biomedical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Clearside Biomedical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Clearside Biomedical and other key companies, straight to your email.

About Clearside Biomedical

Clearside Biomedical (NASDAQ:CLSD) is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for diseases affecting the back of the eye. The company’s proprietary SCS Microinjector® platform enables targeted delivery of therapeutics into the suprachoroidal space, a potential route to enhance local drug exposure while minimizing off-target effects. Clearside’s approach is designed to address a range of retinal disorders by directly depositing medication adjacent to choroid and retina.

The company’s lead approved product is XIPERE® (triamcinolone acetonide injectable suspension), which has received U.S. Food and Drug Administration clearance for the treatment of macular edema associated with uveitis. In addition to XIPERE, Clearside has advanced several pipeline candidates, including CLS-AX (axitinib injectable suspension) for neovascular age-related macular degeneration and other small-molecule and biologic programs leveraging the suprachoroidal route. These programs are in various stages of clinical development, targeting indications such as diabetic macular edema and wet AMD.

Founded in 2010 and headquartered in Alpharetta, Georgia, Clearside Biomedical completed its initial public offering on the Nasdaq Stock Market under the ticker “CLSD.” The company is led by President and Chief Executive Officer Samir Melhem, who has overseen clinical and regulatory milestones, including FDA approval of XIPERE. Clearside continues to explore both U.S. and ex-U.S. partnerships to expand patient access to its suprachoroidal therapies.

View Clearside Biomedical Profile

More Earnings Resources from MarketBeat